A Detailed Analysis of Over-The-Counter (OTC) Veterinary Drugs Market by Oral, Injectable, and Topical
Enhanced Clinical Trials, Technological Advancements, and Higher Pet Adoption is Flourishing the Over-the-counter (OTC) Veterinary Drugs Market. FMI Taps the Data
Over-The-Counter (OTC) Veterinary Drugs Market Outlook
The over-the-counter (OTC) veterinary drugs market is expected to expand its roots at a steady CAGR of 7.9% during the forecast period. The market is likely to hold a revenue of US$ 8.8 billion in 2023 while it is anticipated to cross a value of US$ 19.01 billion by 2033.
The research report on the over-the-counter (OTC) veterinary drugs market states that the higher animal adoption, no need for a prescription, and easy availability is flourishing the market growth. Furthermore, these veterinary medicines can be taken if one follows the directions printed on the drug packaging. The extended list of drugs used on animals and humans along with the allergy medicine for dogs over the counter is garnering the market growth. Alongside this, the higher safety provided by the prescribed drugs has a high price and the cost of a prescription.
The increasing number of cases of pet issues like ticks, pain, viral, and flea fever are being diagnosed and treated with these over-the-counter veterinary drugs. Governments across the globe are pushing the level of support they provide to pet care due to the expansion of the pet industry. For example, the Animal Welfare Board of India has deployed different schemes for the benefit of animal owners in the nation.
Over-the-counter (OTC) veterinary drugs market analysis explains that the availability of these OTC veterinary drugs on e-commerce websites is garnering market growth. The rising awareness around antibiotic resistance has pushed the demand for OTC veterinary drugs. The joint efforts of the government and the organizations are building shelters for stray animals. The pentation of medical services in veterinary spaces along with the advent of antibacterial injection and expanding research and development facilities.
Attributes
Details
Over-The-Counter (OTC) Veterinary Drugs Market CAGR (2023 to 2033)
Customize your report by selecting specific countries or regions and save 30%!
How is the Future Outlook (2023 to 2033) for the Over-The-Counter (OTC) Veterinary Drugs Market in Comparison to the Historical Pattern (2018 to 2022)?
Short-term Growth (2023 to 2026): The increased number of pet adoption, pet humanization, and animal shelter homes is expected to flourish the market growth. The easy availability and expanding veterinary medicines are also expected to fuel the demand for over-the-counter (OTC) veterinary drugs. With these wide ranges of applications, the market is expected to hold US$ 8.8 billion in 2023 while it is anticipated to reach US$ 11.05 billion by 2026.
Mid-term Growth (2026 to 2029): The rising population of aware and animal-friendly people is building pet spaces and making other people aware of pet health. Extending research and development programs are weaponizing the OTC veterinary drugs with anti-fungal, and anti-bacterial properties. This takes a market value from US$ 11.05 billion in 2026 to a value of US$ 13.88 billion in 2029.
Long-term Growth (2029 to 2033): Veterinarians’ preference for wellness, rising awareness of antibiotic resistance, and high demand for pet supplements are some of the key drivers that are expected to fuel the market growth in the period. Thus, the market is anticipated to thrive at a steady CAGR of 7.9% between 2023 and 2033.
What Growth Drivers Flourish in the Market?
The surging sales of over-the-counter (OTC) veterinary drugs are fueled by the availability of OTC animal drugs on e-commerce platforms, affordable rates, and prescription-free drugs. Furthermore, the ease in regulations and the advent of anti-biotic drugs are flourishing the demand for over-the-counter (OTC) veterinary drugs. The rise in personal disposable income along with the enhanced lifestyle has garnered market growth. The clean-label and easily manufactured drugs are spreading in the market for better reach. Government veterinary clinics also consume a big chunk of the OTC veterinary market. The pet parents are looking for medicines that improve the feeding capacity of their pets. The availability of customized medications from compounding pharmacies is another factor propelling the demand in the market. Innovational ideas like flavored soft chews are getting popular in the market space.
Find your sweet spots for generating winning opportunities in this market.
What are the Major Restraints in the Over-The-Counter (OTC) Veterinary Drugs Market?
Some of the major restraints for over-the-counter (OTC) veterinary drugs are restrictive government policies and longer approval status. Furthermore, the specialized spaces for animals that deliver prescribed drugs for animals are also limiting the market growth.
Comparative View
Over-The-Counter (OTC) Veterinary Drugs Market:
Attributes
Over-The-Counter (OTC) Veterinary Drugs Market
CAGR (2023 to 2033)
7.9%
Market Value (2033)
US$ 19.01 billion
Growth Factor
The increased demand for un-prescribed veterinary drugs, higher pet adoption, and humanization, expanding pet accessories, and vet medical stores are flourishing the demand for over-the-cover veterinary drugs.
Opportunity
The government-funded pet shelter homes, increased awareness, clean-label packaging, and pet-health authorities are expected to create new opportunities for the market.
Key Trends
Faster approvals, informative packaging, and lower side effects are flourishing growth trends for the market.
Veterinary Medicine Market:
Attributes
Veterinary Medicine Market
CAGR (2023 to 2033)
8.1%
Market Value (2033)
US$ 27.30 billion
Growth Factor
The increasing prevalence of chronic and zoonotic diseases along with the extended research and development procedures are flourishing the demand for various veterinary drugs.
Opportunity
Authority-supported animal vaccination programs, new pet care companies, and expanding market research are collectively garnering the market opportunities
Key Trends
Disease outbreaks around the world along with the advent of antimicrobial resistance (AMR) fuel the growth trends.
Pet Supplement Market:
Attributes
Pet Supplement Market
CAGR (2023 to 2033)
5.8%
Market Value (2033)
US$ 3.74 billion
Growth Factor
The higher pet adoption and pet humanization are pushing pet parents to look for supplements that provide their pets with high nutrients and are expected to flourish with the market growth.
Opportunity
The companies launching supplements with different vitamins, products, and proteins are expected to fuel new opportunities for the market.
Key Trends
Higher diseases in pets due to the lack of nutritional values are shaping the market trends.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
Region/Country
Revenue Share % (2022)
United States
32.2%
Germany
7.9%
Japan
4.7%
North America
35%
Europe
32%
Why is the United States Considered an Over-The-Counter (OTC) Veterinary Drugs Market Leader?
Rising Pet Adoption, Increased Pet Adoption, and Availability of Pet Insurance to Drive OTC Veterinary Drugs Market
The United States over-the-counter (OTC) Veterinary Drugs market leads in terms of market share in the North American region. The North American region held a market share of 35% in 2022. Though, the United States market held a market share of 25.6% in the global market. The flourishing pet care industry along with a rising number of online pharmacy platforms is garnering the demand for OTC veterinary drugs. The increasing number of pet insurance companies along with their aggressive marketing efforts are projected to raise product awareness. These products are fueling pet owners to adopt OTC veterinary drugs.
How does Germany perform in the Market?
The Advanced Drug Processing, Enhanced Marketing, and Clean-label Packaging are Garnering the Regional Growth
The German market held a market share of 7.9% in 2022 while the European Union held a market share of 32%. The increased rate of pet adoption and pet humanization are flourishing pushing businesses to expand the market element. For example, the Deutsche Hundewesen (VDH) canine association tapped a 20% hike in the sale of pet dogs in 2020. The increased consultation of these OTC veterinary drugs is also adding value to the market growth.
The presence of major OTC veterinary drug producers in the region is also garnering market growth. These producers involve Merck Animal Health, Boehringer Ingelheim, and Virbac S.A. This delivers a higher availability of products in the Country, thereby recording such a higher share in the European Market.
How does India perform in the Over-The-Counter (OTC) Veterinary Drugs Market?
The Indian over-the-counter (OTC) veterinary drugs market thrives at a CAGR of 8.30% between 2023 and 2033. The rapid growth is attributed to the rising number of dual-income households, increased urban settings, and higher pet humanization. The growth is also attributed to the increased number of veterinary drug producers.
Rising pet parents’ awareness of the benefits of companion animals is fuelling the demand for over-the-counter (OTC) veterinary drugs in India. The managing director of Mars Petcare India states that the brand’s business grew 2X from 2019 to 2021, primarily due to the increasing trend of pet adoptions during the pandemic.
Category-Wise Landscape
Category
By Dosage Form
Leading Segment
Oral
Market Share (2022)
76.40%
Category
By Sales Channel
Leading Segment
Online Pharmacies
Market Share (2022)
40%
Lower Pain, Moderate Effectiveness, and Higher Affordability is flourishing the Segment’s Growth
Based on dosage form, oral form leads as it held a major market share of 76.40% in 2022. The growth of this segment is due to higher consumption of consumables. The lower pain proposition along with the effective results are making the segment thrive. Furthermore, the topical drug type is the second most used drug type for animals.
Easy Shipping, Higher Availability, and Better Product Showcasing fuel the Segment’s Success
Based on the sales channel, the online pharmacies segment lead as it held a market share of 40% in 2022. The growth is attributed to higher discounts, smooth shipping, and higher availability of OTC veterinary drugs. Rising demand for home delivery of all OTC drugs among pet owners has given rise to online pharmacies in the global market.
Competition Scenario
The key players in the market focus on getting a higher number of FDA approvals along with extending their research and development activities. Apart from the regulatory approvals, the tie-ups and collaborations also play an important part in the development.
How can Over-The-Counter (OTC) Veterinary Drugs Vendors Providers Scale their Businesses in the Market?
Market players in the market are working on three major strategies.
Vendors try to add nutritional elements to these veterinary drugs that enhance the medicinal effectiveness
Market vendors also add different types of dosage types, expanding the supply chain.
New product launches with a smaller number of side effects and one OTC medicine covering different pain and tics are also becoming a part of the strategy.
Market Developments
In April 2022, Vetoquinol launched Felpreva®, an innovative 3-monthly feline spot-on parasiticide. It’s likely to help a different set of animals.
In February 2021, Dechra Pharmaceuticals signed a licensing agreement with Akston Biosciences for AKS-425c, a once-a-week insulin therapy for Cats.
Elanco Animal Health announced the launch of the First Oral Flea and Tick Product for Cats, Credelio® CAT (lotilaner)
In July 2020, Merck Animal Health announced the FDA approval of their BRAVECTO® 1-MONTH monthly chews for dogs and puppies above 8 weeks of age
Key Players
Zoetis
Boehringer Ingelheim
Virbac S.A.
Hester Biosciences Ltd.
Merck Animal Health
Elanco Animal Health
Ceva Santé Animale
Vetoquinol S.A.
Phibro Animal Health Corporation
Dechra Pharmaceuticals PLC
Kyoritsu Seiyaku Corporation
AlphaVet Animal Health Ltd.
AdvaCare Pharma
Alphafacts Health Solution
Bimeda Animal Health Inc.
Key Segments Covered
By Drug Class:
NSAIDs
Antihistamines
Decongestants & Bronchodilators
Antibacterial
H2 Receptor Antagonists
Nutrients & Supplements
Glucocorticoids
Lubricant eye drops & artificial tears
Anti-parasitic
Antidiarrheal agents
Others
By Product Form:
Oral
Injectable
Topical
Others
By Sales Channel:
Veterinary Hospitals
Veterinary Clinics
Retail Pharmacies
Hypermarkets & Supermarkets
Online Pharmacies
Veterinary Shops
Key Regions Covered:
North America
UNITED STATES
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
United Kingdom
France
Spain
Russia
Rest of Europe
Japan
APEJ
China
India
Malaysia
Singapore
Australia
Rest of Asia Pacific Excluding Japan (APEJ)
MEA
GCC Countries
Israel
South Africa
The Middle East and Africa (MEA)
Frequently Asked Questions
What is the CAGR for Over-The-Counter Veterinary Drugs Market growth?
Through 2033, the market to develop at a CAGR of 7.9%.
How big will the market be in 2033?
By 2033, the market to have expanded to US$ 19.01 billion.
What is the market’s current valuation?
In 2023, the market to reach a worth of US$ 8.8 billion.
How does India perform in the market?
The Indian market can expand at an 8.30% CAGR between 2023 and 2033.
What are the market's significant restraints?
The chief constraints are stringent government laws and a longer approval process.
What is the market share of the United States?
The United States market contributed to 25.6% of the market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. NSAIDs
5.3.2. Antihistamines
5.3.3. Decongestants & Bronchodilators
5.3.4. Antibacterial
5.3.5. H2 Receptor Antagonists
5.3.6. Nutrients & Supplements
5.3.7. Glucocorticoids
5.3.8. Lubricant eye drops & artificial tears
5.3.9. Anti-parasitic
5.3.10. Antidiarrheal agents
5.3.11. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033
6.3.1. Oral
6.3.2. Injectable
6.3.3. Topical
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sales Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Sales Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Sales Channel, 2023 to 2033
7.3.1. Veterinary Hospitals
7.3.2. Veterinary Clinics
7.3.3. Retail Pharmacies
7.3.4. Hypermarkets & Supermarkets
7.3.5. Online Pharmacies
7.3.6. Veterinary Shops
7.4. Y-o-Y Growth Trend Analysis By Sales Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Sales Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Product
9.2.4. By Sales Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Product
9.3.4. By Sales Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Product
10.2.4. By Sales Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Product
10.3.4. By Sales Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Product
11.2.4. By Sales Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Product
11.3.4. By Sales Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Product
12.2.4. By Sales Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Product
12.3.4. By Sales Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Class
13.2.3. By Product
13.2.4. By Sales Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Product
13.3.4. By Sales Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Product
14.1.2.3. By Sales Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Product
14.2.2.3. By Sales Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Product
14.3.2.3. By Sales Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Product
14.4.2.3. By Sales Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Product
14.5.2.3. By Sales Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Product
14.6.2.3. By Sales Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Product
14.7.2.3. By Sales Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Product
14.8.2.3. By Sales Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Product
14.9.2.3. By Sales Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Product
14.10.2.3. By Sales Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Product
14.11.2.3. By Sales Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Product
14.12.2.3. By Sales Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Product
14.13.2.3. By Sales Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Product
14.14.2.3. By Sales Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Product
14.15.2.3. By Sales Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Product
14.16.2.3. By Sales Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Product
14.17.2.3. By Sales Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Product
14.18.2.3. By Sales Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Product
14.19.2.3. By Sales Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Product
14.20.2.3. By Sales Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Product
15.3.4. By Sales Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Zoetis
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Boehringer Ingelheim
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Virbac S.A.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. Hester Biosciences Ltd.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. Merck Animal Health
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. Elanco Animal Health
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. Ceva Santé Animale
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. Vetoquinol S.A.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Phibro Animal Health Corporation
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. Dechra Pharmaceuticals PLC
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
16.1.11. Kyoritsu Seiyaku Corporation
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.11.5.2. Product Strategy
16.1.11.5.3. Channel Strategy
16.1.12. AlphaVet Animal Health Ltd.
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.12.5.2. Product Strategy
16.1.12.5.3. Channel Strategy
16.1.13. AdvaCare Pharma
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.13.5.2. Product Strategy
16.1.13.5.3. Channel Strategy
16.1.14. Alphafacts Health Solution
16.1.14.1. Overview
16.1.14.2. Product Portfolio
16.1.14.3. Profitability by Market Segments
16.1.14.4. Sales Footprint
16.1.14.5. Strategy Overview
16.1.14.5.1. Marketing Strategy
16.1.14.5.2. Product Strategy
16.1.14.5.3. Channel Strategy
16.1.15. Bimeda Animal Health Inc.
16.1.15.1. Overview
16.1.15.2. Product Portfolio
16.1.15.3. Profitability by Market Segments
16.1.15.4. Sales Footprint
16.1.15.5. Strategy Overview
16.1.15.5.1. Marketing Strategy
16.1.15.5.2. Product Strategy
16.1.15.5.3. Channel Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Volume (Units) Forecast by Region, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 4: Global Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 6: Global Market Volume (Units) Forecast by Product, 2018 to 2033
Table 7: Global Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 8: Global Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: North America Market Volume (Units) Forecast by Country, 2018 to 2033
Table 11: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: North America Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 13: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 14: North America Market Volume (Units) Forecast by Product, 2018 to 2033
Table 15: North America Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 16: North America Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Table 17: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Latin America Market Volume (Units) Forecast by Country, 2018 to 2033
Table 19: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 20: Latin America Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 21: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 22: Latin America Market Volume (Units) Forecast by Product, 2018 to 2033
Table 23: Latin America Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 24: Latin America Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Table 25: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Europe Market Volume (Units) Forecast by Country, 2018 to 2033
Table 27: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 28: Europe Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 29: Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 30: Europe Market Volume (Units) Forecast by Product, 2018 to 2033
Table 31: Europe Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 32: Europe Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Table 33: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 34: Asia Pacific Market Volume (Units) Forecast by Country, 2018 to 2033
Table 35: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 36: Asia Pacific Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 37: Asia Pacific Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 38: Asia Pacific Market Volume (Units) Forecast by Product, 2018 to 2033
Table 39: Asia Pacific Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 40: Asia Pacific Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Table 41: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 42: MEA Market Volume (Units) Forecast by Country, 2018 to 2033
Table 43: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 44: MEA Market Volume (Units) Forecast by Drug Class, 2018 to 2033
Table 45: MEA Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 46: MEA Market Volume (Units) Forecast by Product, 2018 to 2033
Table 47: MEA Market Value (US$ Million) Forecast by Sales Channel, 2018 to 2033
Table 48: MEA Market Volume (Units) Forecast by Sales Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Product, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Volume (Units) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 10: Global Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 13: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 14: Global Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 17: Global Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 18: Global Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 22: Global Market Attractiveness by Product, 2023 to 2033
Figure 23: Global Market Attractiveness by Sales Channel, 2023 to 2033
Figure 24: Global Market Attractiveness by Region, 2023 to 2033
Figure 25: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Product, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 29: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 30: North America Market Volume (Units) Analysis by Country, 2018 to 2033
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 33: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 34: North America Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 38: North America Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 39: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 40: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 41: North America Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 42: North America Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 43: North America Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 44: North America Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 45: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 46: North America Market Attractiveness by Product, 2023 to 2033
Figure 47: North America Market Attractiveness by Sales Channel, 2023 to 2033
Figure 48: North America Market Attractiveness by Country, 2023 to 2033
Figure 49: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 50: Latin America Market Value (US$ Million) by Product, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 54: Latin America Market Volume (Units) Analysis by Country, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 57: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 58: Latin America Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 61: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 62: Latin America Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 66: Latin America Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 69: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 70: Latin America Market Attractiveness by Product, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Sales Channel, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 73: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) by Product, 2023 to 2033
Figure 75: Europe Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 78: Europe Market Volume (Units) Analysis by Country, 2018 to 2033
Figure 79: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 80: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 82: Europe Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 83: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 86: Europe Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 87: Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 88: Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 89: Europe Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 90: Europe Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 93: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 94: Europe Market Attractiveness by Product, 2023 to 2033
Figure 95: Europe Market Attractiveness by Sales Channel, 2023 to 2033
Figure 96: Europe Market Attractiveness by Country, 2023 to 2033
Figure 97: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 98: Asia Pacific Market Value (US$ Million) by Product, 2023 to 2033
Figure 99: Asia Pacific Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 100: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 101: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 102: Asia Pacific Market Volume (Units) Analysis by Country, 2018 to 2033
Figure 103: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 104: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 105: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 106: Asia Pacific Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 109: Asia Pacific Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 110: Asia Pacific Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 111: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 112: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 113: Asia Pacific Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 114: Asia Pacific Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 115: Asia Pacific Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 116: Asia Pacific Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 117: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: Asia Pacific Market Attractiveness by Product, 2023 to 2033
Figure 119: Asia Pacific Market Attractiveness by Sales Channel, 2023 to 2033
Figure 120: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Product, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by Sales Channel, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Volume (Units) Analysis by Country, 2018 to 2033
Figure 127: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 128: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 129: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 130: MEA Market Volume (Units) Analysis by Drug Class, 2018 to 2033
Figure 131: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 132: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 133: MEA Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 134: MEA Market Volume (Units) Analysis by Product, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 137: MEA Market Value (US$ Million) Analysis by Sales Channel, 2018 to 2033
Figure 138: MEA Market Volume (Units) Analysis by Sales Channel, 2018 to 2033
Figure 139: MEA Market Value Share (%) and BPS Analysis by Sales Channel, 2023 to 2033
Figure 140: MEA Market Y-o-Y Growth (%) Projections by Sales Channel, 2023 to 2033
Figure 141: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 142: MEA Market Attractiveness by Product, 2023 to 2033
Figure 143: MEA Market Attractiveness by Sales Channel, 2023 to 2033
Figure 144: MEA Market Attractiveness by Country, 2023 to 2033
